Navigation Links
Response to preoperative therapy may predict survival in pancreatic cancer patients
Date:5/28/2010

CHICAGO, IL. (May 28, 2010)Cancer of the pancreasa glandular organ that lies behind the stomach and secretes vital enzymes and hormonesseldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

The research, led by Yun Shin Chun, M.D., a surgical oncologist at Fox Chase, will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 6.

Since the 1980s, Fox Chase has been committed to finding better treatments for this intractable disease. In 1986, the Center conducted the first trial in pancreatic cancer of "multimodal" preoperative therapy (the use of more than one kind of treatment, such as chemotherapy and radiation, to kill tumor cells before surgery), and a phase I trial of gemcitabine in the 1990s established the safe dosage for the chemotherapy drug, now widely used in treating the disease.

In the current study, Chun and colleagues wanted to know whether response to preoperative therapy predicts survival in pancreatic adenocarcinomathe most common type of pancreatic cancer. "For many cancersbreast, esophagus, stomach, and colorectal liver metastasesit has been shown that survival is much better in people who have a good pathologic response to preoperative therapymeaning that many tumor cells are killedthan in people who do not have a good pathologic response," says Chun. "But this has not been established in pancreatic cancer; previous studies have shown conflicting results."

In hopes of clearing up the confusion, Chun and colleagues reviewed data on 135 patients who had preoperative therapy and surgery. Fox Chase pathologist Harry Cooper, M.D., examined slides of the patients' tumors and classified their response to preoperative treatment as minor, partial, or major, based on the amount of fibrosis (scarring) in tumor tissue. For patients whose tumors showed major response to preoperative therapy, the median survival was more than five years, compared to seventeen months for those who showed minor response.

Although major response is relatively rareonly 19 percent of patients in the study were so classifiedthe findings give researchers and clinicians important information to build upon. "Going forward, if we can identify molecular factors in tumors associated with a major pathologic response, then we can make important progress in this disease," says Dr. Chun.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses
2. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
3. Unique Marketing Approach to the Energy Drink Market Brings Explosive Response
4. Response to vaccines could depend on your sex
5. Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
6. Babies Responses to Prenatal Stress Differ by Gender
7. A stress-response system in the ear protects against hearing loss
8. Patients whole genome reveals risk of diseases and adverse drug responses
9. Merely seeing disease symptoms may promote aggressive immune response
10. Protein in Breast Tumors May Predict Chemo Response
11. Bodys Response to Foods Smell, Taste Could Be Diabetes Risk Factor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: